UBS Maintains Neutral on CME Group, Raises Price Target to $270
UBS analyst Alex Kramm maintains CME Group (NASDAQ:CME) with a Neutral and raises the price target from $260 to $270.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga